Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials.

@article{Mori2011EtanerceptIT,
  title={Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials.},
  author={Masaaki Mori and Syuji Takei and Tomoyuki Imagawa and Hiroyuki Imanaka and Yasuhito Nerome and Rumiko Kurosawa and Yoshifumi Kawano and Shumpei Yokota and Noriko Sugiyama and Hirotoshi Yuasa and T. H. Fletcher and Joseph S Wajdula},
  journal={Modern rheumatology},
  year={2011},
  volume={21 6},
  pages={572-8}
}
Efficacy, safety, and pharmacokinetics results from 4 studies-3 open-label (OL) and 1 randomized double-blind (DB)-have provided data for approval of etanercept for treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory juvenile idiopathic arthritis (JIA) in Japan. Results from the 3 shorter-term (2 OL and 1 DB) studies are reported here. Subjects (4-17 years) enrolled in the OL studies had active JIA, i.e. ≥5 swollen joints and ≥3 joints with limitation of motion and pain or… CONTINUE READING
3 Citations
14 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 14 references

Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register

  • FH Prince, M Twilt, R ten Cate, MA van Rossum, W Armbrust, EP Hoppenreijs
  • Ann Rheum Dis
  • 2009

Similar Papers

Loading similar papers…